Evaluation of Accuracy of the Owlet OSS 3.0 Sensor in the Neonatal Population
NCT ID: NCT06771206
Last Updated: 2025-08-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
20 participants
INTERVENTIONAL
2025-08-01
2026-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The Owlet OSS 3.0 is the Sensor component within the Owlet Dream Sock, an over the counter, noninvasive pulse oximeter which is currently FDA cleared in infants 1-18 months and between 6 and 30lbs, meant to be used in the home environment. The Owlet Sock is a fabric wrap that secures the Sensor to a baby's foot. The Sensor estimates the baby's SpO2, pulse rate, and measures movement level, and transmits the wearer's readings to the paired Base Station via low energy BlueTooth energy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neonatal Pulse Oximetry Sensor Study
NCT05250102
Bradycardia Recognition and Detection in Young Infants Part-I
NCT05774470
An Observational Study of Skin Reaction in Infants Using the Owlet Sock OSS 3.0
NCT05561946
Validity and Feasibility of Newborn Bed Monitoring Device - a Clinical Pilot Study
NCT06679127
Transcutaneous Partial Oxygen and Carbon Dioxide Pressures Compared With Blood Gas Values
NCT03060018
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The Owlet OSS 3.0 Sensor is the component of the Owlet Dream Sock (DEN220091) and BabySat (K222597), both Food and Drug Administration (FDA) cleared pulse oximeters for infants 1-18 months in 2023. This component performs the signal acquisition and analysis to estimate pulse rate and SpO2 readings.
The study will enroll between 20-100 neonates weighing a minimum of 1500g in the hospital setting with available arterial line access and arterial blood gas samples being performed as part of planned patient management. No additional blood gas samples will be taken beyond clinical care indications.
The primary outcome of the study is the accuracy of the Owlet OSS 3.0 Sensor SpO2 readings compared to simultaneous arterial saturation (SaO2) measurements from arterial blood gas samples as determined by a root mean square (ARMS) calculation.
Secondary outcomes will include:
* Bias in the Owlet OSS 3.0 Sensor SpO2 vs SaO2 defined as (Owlet OSS 3.0 Sensor SpO2 - SaO2).
* Precision of the Owlet OSS 3.0 Sensor SpO2 vs SaO2 defined as ABS (Owlet OSS 3.0 Sensor SpO2 - SaO2).
Accuracy will be stratified by a number of demographic elements, including by a 10 point skin tone scale and Individual Typology Angle (ITA) as determined by a spectrophotometer to demonstrate that the sensor technology under test can be accurate across diverse user populations.
The primary hypothesis is that the Owlet OSS 3.0 Sensor will measure SpO2 values within +/- 3% ARMS compared to SaO2 measurements.
Each study participant will have a total study exposure time of 48 hours. Each participant will be assigned to a unique Owlet device with a specific serial number which will be paired with the study subject identifier. The Owlet OSS 3.0 Sensor will be attached to a study subject's foot and SpO2 readings will be acquired at a set frequency and time-aligned with arterial blood gas sampling performed during the course of routine patient care. Study operators will be blinded to Owlet device readings. Time stamping of Owlet SpO2 readings will be achieved by a prescribed tapping of the device's Base Station which will mark the point at which readings simultaneous to the blood gas sample were recorded. SpO2 readings from the available noninvasive reference pulse oximeter will also be recorded during the time of blood gas sampling to document the subject's baseline SpO2 plateau.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Owlet Arm
All study participants meeting inclusion criteria with no stated exclusions will wear the Owlet OSS 3.0 Sensor during the study intervention. The Owlet OSS 3.0 Sensor may be placed continuously on a study subject for up to 48 hours with rotation to the opposite foot every 8 hours per device labeling to enable noninvasive data collection during the subject's standard of care blood draws. The Owlet base station will be activated in order to transmit readings but will not provide any external alarms or live displays during the monitoring period. No display of readings from the assigned Owlet device will be made available to the participant or the investigators during the time of data acquisition.
Owlet pulse oximeter neonatal accuracy validation
This study specifically evaluates the Owlet pulse oximetry sensor, which is specifically designed and FDA cleared for for infants, and whose accuracy is specifically being validated in the neonate population.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Owlet pulse oximeter neonatal accuracy validation
This study specifically evaluates the Owlet pulse oximetry sensor, which is specifically designed and FDA cleared for for infants, and whose accuracy is specifically being validated in the neonate population.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Weight equal or greater than 1500g
* Subjects with standard of care (SOC) arterial blood sampling line already in place at time of enrollment, with anticipated arterial blood gas measurements as part of their plan of care
Exclusion Criteria
* Subjects with abnormalities (e.g., limb deformities, open wounds, severe edema) at the planned application sites that would interfere with system measurements
* Potential subjects on extracorporeal membrane oxygenation (ECMO) or other mechanical circulatory support
* Arterial line is placed in a preductal position with the potential of pulmonary to systemic shunting
* Subjects undergoing cooling protocol/therapeutic hypothermia
* Subjects who are deemed too clinically unstable by the Principal Investigator (PI), sub-investigator and/or clinical care team to participate in the study.
0 Days
28 Days
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Children's of Alabama
OTHER
University of Minnesota
OTHER
Owlet Baby Care, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gwenyth Fischer, M.D.
Role: PRINCIPAL_INVESTIGATOR
University of Minnesota Medical Center
Michael A Brock, M.D.
Role: PRINCIPAL_INVESTIGATOR
University of Alabama Birmingham - Children's of Alabama
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama Birmingham - Children's of Alabama
Birmingham, Alabama, United States
University of Minnesota Medical Center
Minneapolis, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Okunlola OE, Lipnick MS, Batchelder PB, Bernstein M, Feiner JR, Bickler PE. Pulse Oximeter Performance, Racial Inequity, and the Work Ahead. Respir Care. 2022 Feb;67(2):252-257. doi: 10.4187/respcare.09795. Epub 2021 Nov 12.
Sjoding MW, Dickson RP, Iwashyna TJ, Gay SE, Valley TS. Racial Bias in Pulse Oximetry Measurement. N Engl J Med. 2020 Dec 17;383(25):2477-2478. doi: 10.1056/NEJMc2029240. No abstract available.
Wackernagel D, Blennow M, Hellstrom A. Accuracy of pulse oximetry in preterm and term infants is insufficient to determine arterial oxygen saturation and tension. Acta Paediatr. 2020 Nov;109(11):2251-2257. doi: 10.1111/apa.15225. Epub 2020 Mar 6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OWL PR0007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.